Center for Epidemiology and Preventive Medicine, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
PLoS One. 2022 Jun 17;17(6):e0270252. doi: 10.1371/journal.pone.0270252. eCollection 2022.
The increasing usage of proton pump inhibitors (PPIs) has been reported worldwide, but information on PPI use in East Asia is inadequate. This study aimed to examine the trends in PPI use in Japan, along with the changes in histamine H2 receptor antagonist (H2RA) use, disease rate of reflux esophagitis, and the prevalence of upper gastrointestinal symptoms. We analyzed 217,712 healthy subjects (127,607 men and 90,105 women; 51.4 ± 9.7 years old) participating in the health check program from 2010 to 2019. Various upper gastrointestinal symptoms were evaluated using the frequency scale for the symptoms of gastroesophageal reflux disease (FSSG) questionnaire. Reflux esophagitis was diagnosed by esophageal erosion using the Los Angeles classification grades A, B, C, and D. From 2010 to 2019, the percentage of PPI users increased markedly from approximately 1.8% to 5.3%, whereas that of H2RA users decreased gradually from approximately 2.5% to 1.9%. The use of all classical types of PPIs (omeprazole, lansoprazole, rabeprazole, and esomerazole) and a new type of PPI, a potassium-competitive acid blocker (vonoprazan), greatly increased during the 10 years. An upward trend in the prevalence of reflux esophagitis was observed from 2010 to 2015, but not from 2016 to 2019, indicating that the monotonic rising prevalence of reflux disease stopped in the middle of the 2010s in Japan. In contrast, various upper gastrointestinal symptoms significantly improved between 2010 and 2019. All 12 FSSG symptoms of PPI users were significantly worse than those of non-PPI users, suggesting that PPIs still cannot completely control upper gastrointestinal symptoms. In conclusion, this study revealed a significant increase in PPI use and a slight decrease in H2RA use from 2010 to 2019. Despite a plateau in the prevalence of reflux esophagitis and considerable improvement in various upper gastrointestinal symptoms, PPI use has continued to increase in Japan.
质子泵抑制剂 (PPI) 的使用量在全球范围内不断增加,但东亚地区关于 PPI 使用情况的信息还不够充分。本研究旨在探讨日本 PPI 使用趋势,以及组胺 H2 受体拮抗剂 (H2RA) 使用、反流性食管炎发病率和上消化道症状的流行率的变化。我们分析了 2010 年至 2019 年参加健康检查计划的 217712 名健康受试者(男性 127607 名,女性 90105 名;51.4±9.7 岁)。使用胃食管反流病症状频率量表 (FSSG) 问卷评估各种上消化道症状。使用洛杉矶分类 A、B、C 和 D 级食管侵蚀诊断反流性食管炎。从 2010 年到 2019 年,PPI 用户的比例从约 1.8%显著增加到 5.3%,而 H2RA 用户的比例从约 2.5%逐渐减少到 1.9%。所有经典类型的 PPI(奥美拉唑、兰索拉唑、雷贝拉唑和埃索美拉唑)和一种新型 PPI(钾竞争型酸阻滞剂)的使用在 10 年内大大增加。从 2010 年到 2015 年,反流性食管炎的患病率呈上升趋势,但从 2016 年到 2019 年没有上升趋势,这表明日本反流性疾病的单调上升患病率在 2010 年代中期停止。相比之下,各种上消化道症状在 2010 年至 2019 年间均显著改善。所有 12 项 PPI 用户的 FSSG 症状均明显差于非 PPI 用户,表明 PPI 仍不能完全控制上消化道症状。总之,本研究表明,从 2010 年到 2019 年,PPI 的使用显著增加,H2RA 的使用略有减少。尽管反流性食管炎的患病率出现了平台期,各种上消化道症状也有了显著改善,但 PPI 在日本的使用仍在继续增加。